Table 1 Patient characteristics, responses and outcomes for enrolled patients with LBCL

From: CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Patient ID

Dose levela

Age/sex

Disease

DEL/DHL

Lines of therapy

SPDb

Pre-lymphodepletion LDH

Maximum CRS

Maximum neurotoxicity

Best response (PFS)c

CD19 H-score at progression

CD19 site density at progressiond

CD22 H-score at progression

CD22 site density at progression

SL1

1

71/M

DLBCL

DEL + DHL

3

141.08

788

1

2

PD (1)

>90% flow

–

95% flow

–

SL2

1

54/M

TFL

DEL

3

129.9

614

0

0

PR (5)

150

–

0

–

SL3

1

67/M

DLBCL

DEL

4

5.5

254

0

0

PD (1)

210

–

240

–

SL5

1

75/M

DLBCL

–

2

8.35

223

3

0

CR (22+)

–

–

–

–

SL6

1

67/M

DLBCL

–

2

16.12

196

1

1

PR (5)

>95% flow

–

>60% flow

–

SL10

2

70/M

DLBCL

DEL

2

5.6

222

1

0

SD (2)

270

8682

285

38,002

SL11

2

25/F

PMBCL

DEL

2

96.48

335

0

0

PR (5)

180

1150

270

1,046

SL12

2

70/F

DLBCL

DEL

2

36.39

326

1

0

PR (3)

285

–

285

 

SL14

2

64/M

TFL

DHL

2

60.68

291

1

0

CR (14+)

–

–

–

–

SL15

2

77/M

DLBCL

DHL

4

93.07

1563

1

1

SD (1)

>90% flow

5446

26% flow

1,942

SL16

2

66/F

DLBCL

–

2

14.35

201

1

0

PD (1)

270

–

0

–

SL17

2

71/M

TFL

N/A

3

61.36

312

N/A

N/A

Not infused

N/A

N/A

N/A

N/A

SL18

2

75/M

DLBCL

DEL

4

47.63

274

2

3

PR (3)

Not biopsied

–

–

–

SL19

2

67/F

DLBCL

DEL

2

4.93

177

1

2

PD (1)

0

–

90

–

SL20

2

69/F

Richtere

DEL

7

2.72

130

1

0

PD (1)

30

–

150

–

SL21

2

59/F

DLBCLe

DEL

4

0.6

250

1

0

CR (6)

0

110

100

2,888

SL22

1

34/F

PMBCL

DEL

2

29.96

336

0

0

PR (9)

300

–

300

–

SL23

2

70/M

Richter

DEL

3

39.1

220

1

1

SD (3)

300

21092

300

12,492

SL25

2

78/M

DLBCLe

DEL

4

5.18

200

2

1

CR (11+)

–

–

–

–

SL27

2

76/M

DLBCL

DEL

3

6.6

246

1

1

PR (3)

Not biopsied

–

–

–

SL28

2

73/M

DLBCLe

N/A

4

9.07

200

0

0

CR (10+)

–

–

–

–

SL31

2

60/M

TFL

DEL

4

35.94

197

2

2

CR (10+)

–

–

–

–

  1. aDL1 was 1 × 106 cell kg−1; DL2 was 3 × 106 cells kg−1. bSPD was calculated by summing the products of the cross-sectional diameters of the preinfusion index lesions in cm2. cLymphoma responses were assessed according to Cheson et al.65. PFS was determined from the date of infusion until progression or death. The + symbol indicates ongoing response. dCD19 positivity by site density was >3,000 molecules per cell. ePrevious autologous stem cell transplant. DEL, double expressor lymphoma; DHL, double-hit lymphoma; DLBCL, diffuse large B cell lymphoma; PMBCL, primary mediastinal B cell lymphoma; SPD, sum product of diameters; TFL, transformed follicular lymphoma.
Back to article page